Stock Events

Stock Events

MIRO SCIENCES LTD. 

€0.018100
0
+€0.00+0%Monday 20:42

Statistics

Day High
0.0183
Day Low
0.0181
52W High
0.0183
52W Low
0.0181
Volume
-
Avg. Volume
-
Mkt Cap
7.05M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap37.49B
Biogen focuses on neurodegenerative diseases, similar to NSB's focus on neurological disorders.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly has a strong portfolio in Alzheimer's disease treatments, directly competing with NSB's Alzheimer's projects.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG has significant investments in neuroscience and Alzheimer's disease, overlapping with NSB's research areas.
Pfizer
PFE
Mkt Cap173.95B
Pfizer has a history of developing treatments for neurological conditions, competing in the same therapeutic area as NSB.
Novartis
NVS
Mkt Cap303.67B
Novartis offers several products for neurological conditions, making it a direct competitor in the neurology sector.
Merck
MRK
Mkt Cap368.89B
Merck & Co. is involved in developing therapies for Alzheimer's disease, which is a key area for NSB.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie has a growing interest in neurodegenerative diseases, particularly Alzheimer's, competing with NSB's focus.
AMGEN
AMGN
Mkt Cap251.94B
Amgen has research initiatives in neuroscience, including Alzheimer's disease, positioning it as a competitor to NSB.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson conducts extensive research in neuroscience, making it a competitor in the neurological space.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca has a dedicated neuroscience R&D unit, which competes with NSB in developing neurological disorder treatments.

About

Established in 2002 and headquartered in Cottesloe, Australia, NeuroScientific Biopharmaceuticals Limited specializes in the development of medical therapies for neurodegenerative conditions. The company conducts extensive preclinical and clinical research utilizing its proprietary technological platforms to advance these treatments. Its primary pharmaceutical compound, EmtinB, is being developed as a potential therapeutic agent for diseases including neurodegenerative dementia, Alzheimer's disease, and various degenerative disorders affecting the optic nerve.
Show More
CEO
Nathan Smith
Employees
9
Country
Australia
ISIN
AU0000496887
WKN
000A3DPPS

Listings

AU
AU
NSB.AU
AU
AU
MSX.AU
F
DE
NBM0.F

0 Comments

Share your thoughts

FAQs

What is MIRO SCIENCES LTD. stock price today?▼
The current price of NBM0.F is €0.02 EUR — it has increased by +0% in the past 24 hours. Watch MIRO SCIENCES LTD. stock price performance more closely on the chart.
What is MIRO SCIENCES LTD. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange MIRO SCIENCES LTD. stocks are traded under the ticker NBM0.F.
What is MIRO SCIENCES LTD. market cap?▼
Today MIRO SCIENCES LTD. has the market capitalization of 7.05M
How many employees does MIRO SCIENCES LTD. have?▼
As of November 3, 2026, the company has 9 employees.
In which sector is MIRO SCIENCES LTD. located?▼
MIRO SCIENCES LTD. operates in the Health & Wellness sector.
When did MIRO SCIENCES LTD. complete a stock split?▼
MIRO SCIENCES LTD. has not had any recent stock splits.
Where is MIRO SCIENCES LTD. headquartered?▼
MIRO SCIENCES LTD. is headquartered in Perth, Australia.